{
    "clinical_study": {
        "@rank": "134304", 
        "arm_group": {
            "arm_group_label": "Vandetanib 300mg", 
            "arm_group_type": "Experimental", 
            "description": "300 mg/day vandetanib"
        }, 
        "brief_summary": {
            "textblock": "Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in\n      Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid\n      Carcinoma."
        }, 
        "brief_title": "Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Thyroid Neoplasms", 
                "Thyroid Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300\n      mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary\n      Thyroid Carcinoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written consent from female or male Japanese patients aged 20 years and over.\n             Evidence of non-childbearing status for women of childbearing potential, or\n             postmenopausal status.\n\n          -  Previous diagnosis of unresectable, locally advanced or metastatic, hereditary or\n             sporadic Medullary Thyroid Carcinoma(MTC).\n\n          -  Patients who have a good overall health status(World Health Organization (WHO)\n             Performance status 0-2).\n\n          -  Patients who have appropriate renal conditions confirmed by test results for taking\n             part in the study.\n\n          -  For patients with measurable disease(at least one lesion, not irradiated within 12\n             weeks of study registration, with longest diameter more or equal 10mm (lymph nodes\n             minimum more or equal 15 mm) with CT or MRI).\n\n        Exclusion Criteria:\n\n          -  Patients with brain metastases or spinal cord compression.\n\n          -  Patients with significant abnormal ECG (QTcB correction unmeasurable or more than 480\n             ms)findings and /or significant cardiac conditions or events, uncontrolled\n             hypertension and evidence of severe lung disease.\n\n          -  Abnormal electrolytes such as potassium, magnesium and calcium, or abnormal organ\n             functions such as decreased creatinine clearance.\n\n          -  Patients with significant abnormal laboratory findings (to include abnormal liver\n             function tests (bilirubin more than 1.5xULRR, and ALT, AST, or ALP more than 2.5xULRR\n             or 5.0xULRR if related to liver metastases).\n\n          -  Prior treatment (major surgery, radiation therapy, chemotherapy, or other\n             investigational drugs) received within 28 days before registration."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01661179", 
            "org_study_id": "D4200C00098"
        }, 
        "intervention": {
            "arm_group_label": "Vandetanib 300mg", 
            "description": "300 mg oral dose once daily (100 mg x 3 tablets)", 
            "intervention_name": "Vandetanib 300mg", 
            "intervention_type": "Drug", 
            "other_name": "ZD6474"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Medullary Thyroid Carcinoma", 
            "Medullary Thyroid Cancer", 
            "Vandetanib"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kobe-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koto-ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma", 
        "overall_official": [
            {
                "affiliation": "AstraZeneca", 
                "last_name": "Jeffrey Skolnik, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Tokyo Women's Medical University Hospital", 
                "last_name": "Takahiro Okamoto, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "National Hospital Organization Kyushu Medical Center", 
                "last_name": "Keita Uchino, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Frequency and severity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "During the treatment period and than up to 60 days after treatment period"
            }, 
            {
                "measure": "QTc Bazett's absolute values", 
                "safety_issue": "Yes", 
                "time_frame": "During the treatment period and than up to 60 days after treatment period"
            }, 
            {
                "measure": "Vital signs including pulse rate, blood pressure and temperature", 
                "safety_issue": "Yes", 
                "time_frame": "During the treatment period and than up to 60 days after treatment period"
            }, 
            {
                "measure": "Haematology and clinical chemistry absolute values", 
                "safety_issue": "Yes", 
                "time_frame": "During the treatment period and than up to 60 days after treatment period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01661179"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and 85, 169, 253, 337 and 421 days post first dose"
            }, 
            {
                "description": "PK parameters for multiple dose: Maximum Concentration (Cmax),Time to Maximum Plasma Concentration (tmax), and Area Under Curve (AUC)", 
                "measure": "Pharmacokinetics of vandetanib", 
                "safety_issue": "No", 
                "time_frame": "8,15,22,29,57,85,113,141,169,197,225,253 days post first dose"
            }, 
            {
                "description": "Relationship between vandetanib plasma concentration and effect on QTc. If appropriate, concentration-effect relationships will be explored.", 
                "measure": "Relationship between pharmacokinetics and pharmacodynamics.", 
                "safety_issue": "No", 
                "time_frame": "8,15,22,29,57,85,113,141,169,197,225,253 days post first dose"
            }, 
            {
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose and 85, 169, 253, 337 and 421 days post first dose"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}